These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 20071572)

  • 41. Development of Clade-Specific and Broadly Reactive Live Attenuated Influenza Virus Vaccines against Rapidly Evolving H5 Subtype Viruses.
    Boonnak K; Matsuoka Y; Wang W; Suguitan AL; Chen Z; Paskel M; Baz M; Moore I; Jin H; Subbarao K
    J Virol; 2017 Aug; 91(15):. PubMed ID: 28490598
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cross-clade protection against HPAI H5N1 influenza virus challenge in BALB/c mice intranasally administered adjuvant-combined influenza vaccine.
    Yang P; Tang C; Luo D; Zhan Z; Xing L; Duan Y; Jia W; Peng D; Liu X; Wang X
    Vet Microbiol; 2010 Nov; 146(1-2):17-23. PubMed ID: 20888151
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Multiple-clade H5N1 influenza split vaccine elicits broad cross protection against lethal influenza virus challenge in mice by intranasal vaccination.
    Yang P; Duan Y; Zhang P; Li Z; Wang C; Dong M; Tang C; Xing L; Gu H; Zhao Z; Liu X; Zhang S; Wang X
    PLoS One; 2012; 7(1):e30252. PubMed ID: 22279575
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
    Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
    Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
    Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
    Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Innate immunemodulator containing adjuvant formulated HA based vaccine protects mice from lethal infection of highly pathogenic avian influenza H5N1 virus.
    Lu Y; Landreth S; Liu G; Brownlie R; Gaba A; Littel-van den Hurk SVD; Gerdts V; Zhou Y
    Vaccine; 2020 Feb; 38(10):2387-2395. PubMed ID: 32014270
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and protective efficacy of cold-adapted X-31 live attenuated pre-pandemic H5N1 influenza vaccines.
    Jang YH; Jung EJ; Byun YH; Lee KH; Lee EY; Lee YJ; Seong BL
    Vaccine; 2013 Jul; 31(33):3339-46. PubMed ID: 23742997
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Monovalent H5 vaccine based on epitope-chimeric HA provides broad cross-clade protection against variant H5N1 viruses in mice.
    He F; Prabakaran M; Rajesh Kumar S; Tan Y; Kwang J
    Antiviral Res; 2014 May; 105():143-51. PubMed ID: 24637255
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antibody breadth and protective efficacy are increased by vaccination with computationally optimized hemagglutinin but not with polyvalent hemagglutinin-based H5N1 virus-like particle vaccines.
    Giles BM; Bissel SJ; Dealmeida DR; Wiley CA; Ross TM
    Clin Vaccine Immunol; 2012 Feb; 19(2):128-39. PubMed ID: 22190399
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens.
    Wu Q; Fang L; Wu X; Li B; Luo R; Yu Z; Jin M; Chen H; Xiao S
    Mol Immunol; 2009 Jul; 46(11-12):2210-7. PubMed ID: 19446339
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mucosal immunization with recombinant influenza hemagglutinin protein and poly gamma-glutamate/chitosan nanoparticles induces protection against highly pathogenic influenza A virus.
    Moon HJ; Lee JS; Talactac MR; Chowdhury MY; Kim JH; Park ME; Choi YK; Sung MH; Kim CJ
    Vet Microbiol; 2012 Dec; 160(3-4):277-89. PubMed ID: 22763171
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction of cross-protective immunity against influenza A virus H5N1 by an intranasal vaccine with extracts of mushroom mycelia.
    Ichinohe T; Ainai A; Nakamura T; Akiyama Y; Maeyama J; Odagiri T; Tashiro M; Takahashi H; Sawa H; Tamura S; Chiba J; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2010 Jan; 82(1):128-37. PubMed ID: 19950232
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Baculovirus surface display of the HA protein of H5N2 avian influenza virus and its immunogenicity against a lethal challenge with H5N1 virus in chickens.
    Tung MC; Lu HY; Chang YK; Huang WR; Liao TL; Wu HY; Chang CD; Fan HC; Nielsen BL; Liu HJ
    Vet Microbiol; 2020 Apr; 243():108640. PubMed ID: 32273019
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.
    Mayrhofer J; Coulibaly S; Hessel A; Holzer GW; Schwendinger M; Brühl P; Gerencer M; Crowe BA; Shuo S; Hong W; Tan YJ; Dietrich B; Sabarth N; Savidis-Dacho H; Kistner O; Barrett PN; Falkner FG
    J Virol; 2009 May; 83(10):5192-203. PubMed ID: 19279103
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A viable recombinant rhabdovirus lacking its glycoprotein gene and expressing influenza virus hemagglutinin and neuraminidase is a potent influenza vaccine.
    Ryder AB; Buonocore L; Vogel L; Nachbagauer R; Krammer F; Rose JK
    J Virol; 2015 Mar; 89(5):2820-30. PubMed ID: 25540378
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hemagglutinin amino acids related to receptor specificity could affect the protection efficacy of H5N1 and H7N9 avian influenza virus vaccines in mice.
    Xu L; Bao L; Lau SY; Wu WL; Yuan J; Gu S; Li F; Lv Q; Xu Y; Pushko P; Chen H; Qin C
    Vaccine; 2016 May; 34(23):2627-33. PubMed ID: 27083426
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of a Recombinant Turkey Herpesvirus H5 Vaccine Against Challenge With H5N1 Clades 1.1.2 and 2.3.2.1 Highly Pathogenic Avian Influenza Viruses in Domestic Ducks (Anas platyrhynchos domesticus).
    Pantin-Jackwood MJ; Kapczynski DR; DeJesus E; Costa-Hurtado M; Dauphin G; Tripodi A; Dunn JR; Swayne DE
    Avian Dis; 2016 Mar; 60(1):22-32. PubMed ID: 26953940
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies.
    Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA
    J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Immunization with baculovirus displayed H6 hemagglutinin vaccine protects mice against lethal H6 influenza virus challenge.
    Musthaq SK; Kumar SR; Szyporta M; Kwang J
    Antiviral Res; 2014 Sep; 109():42-53. PubMed ID: 24973759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.